The Innovative Health Initiative (IHI):
The Industry's vision for addressing the future challenges of healthcare: the value of public-private partnerships

Nicolas Creff, Associate Director Research Partnerships, EFPIA
Enrique Esquivel, Strategy & Innovation Manager, COCIR
Jeroen Schuermans, Director Strategic Initiatives, MedTech Europe

Infoday Horizon Europe – EU Partnerships: Innovative Health Initiative | New Call 13
6 July 2026

efpia MedTech Europe from diagnosis to cure COCIR Advancing Healthcare Vaccines Europe An industry for healthy lives EuropaBio The European Association for Bioindustries

Outline

1. Introducing the Trade Associations: who we are, what we do and what is our role in IHI?
2. Why participate in IHI calls?
3. How to participate in IHI?
4. How to engage with industry?

The Innovative Health Initiative

- A public-private partnership (PPP)
- Co-founded by the European Union and the health industries (pharma and medtech):
- Established under Horizon Europe, successor to the IMI2 PPP
- General objectives:
  - Turn health research and innovation into real **benefits for patients and society**
  - Deliver **safe, effective health innovations** that cover the **entire spectrum of care** – from prevention to diagnosis and treatment
  - Make Europe's **health industries globally competitive**.
- Budget:
  - €1.2 billion EU funding,
  - €1 billion contribution from industry (+ 0.2 bln from contributing partners

Who are the healthcare industries in IHI?

Trade Association	Represents	Mission/Vision
EFPIA	Pharmaceutical industry	To create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy.
COCIR	Medical imaging, radiotherapy, health ICT and electromedical industries	Our industry delivers innovative, data-driven, safe and efficient diagnostic imaging, radiotherapy and digital health solutions for personalized and sustainable care that benefits patients, health professionals and healthcare system.
MedTech Europe	Medical Technology industry	Make innovative medical technology available to more people, while helping healthcare systems move towards a more sustainable path.
Vaccines Europe	Vaccine industry	To support broad access to immunisation, enabling better protection of the health of individuals and the wider community throughout life, with both existing vaccines and those in development.
EuropaBio	Biotech industry	Committed to the socially responsible use of biotechnology to improve quality of life, to prevent, diagnose, treat and cure diseases, to improve the quality and quantity of food and feedstuffs and to move towards a biobased and zero-waste economy.

More details: *check our respective websites, and all details in the presentation backups.*

What do associations do in IHI?

What do associations do in general?

Represent the respective healthcare industry sector vis-à-vis the EU Institutions and other stakeholders

What do associations do in IHI?

- **Represent** the respective healthcare industry sector in IHI
- We provide **support related to industry participation in IHI**:
  - We do not replicate the work of the IHI Office
  - We are not consultancies: we do not support proposal preparation or bilateral matchmaking
  - We are active in providing tailored information (e.g. how to engage with industry)
  - We collect and address feedback from stakeholders towards industry

Industry associations: membership

Who are our members who can contribute on the industry side?

→ Companies that are:

- **Direct members of the European Associations**
  (COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe)
- **Members of national associations:**
  - Medtech: Confindustria Dispositivi Medici
  - Pharma: Farmindustria: website, list of members

  For all countries: see table here

See also industry one-pager: *How can my organisation contribute in-kind to an IHI project?*

Outline

1. Introducing the Trade Associations: who we are, what we do and what is our role in IHI?
2. Why participate in IHI calls?
3. How to participate in IHI calls?
4. How to engage with industry?

Healthcare stakeholders: Potential participants to projects



The complementary value that the industry brings to the table

Example on rare diseases:



IHI for companies: value of participating in IHI

- **Strategic commitment** and investment in the **long term**
- **Pre-competitive**: no product around the corner
- Collaboratively **building landscape** for long term European research and healthcare
- **Share and pool knowledge** – be part of long-term shaping of Europe
- Grant **funding should not be driver** for industry participation *
- Most industrial engagement will be through in-kind contribution

Advice we give companies to consider for a role into a project:

- Within your **capacity to contribute diverse expertise, knowledge, experience, and resources**
- Part of wider organisation **strategic development**
- **Long term**, slower moving than 'normal' projects

** NB: EFPIA policy is to not request EU funding in any IHI calls (single or two-stage).*
Only exception: SMEs and midcaps

Outline

1. Introducing the Trade Associations: who we are, what we do and what is our role in IHI?
2. Why participate in IHI calls?
3. How to participate in IHI calls?
4. How to engage with industry?

2 types of calls

Single-stage (e.g. Call 12, launched in Jan 2026 – closed in April 2026)

- **Broad topics**, not specific to one single product/technology/solution
- **Private Members apply simultaneously with Public Members in mixed consortia** and co-develop their proposal for the single application
- Private Members can receive funding, but Pharma companies abstain from requesting funding
- **In-kind contributions** by private and contributing partners must be **secured during proposal preparation**

Two-stage

(e.g. Call 13, launch July 2026 – deadline October 2026)

- **Targeted topics** suited for a single, unified approach
- **Industry and public consortia are formed separately**
- Public consortia submit competing short proposals in the first round of the call
- A single top-ranked public consortium is selected and paired up with the industry consortium to prepare a joint, full proposal
- Private Members are not eligible for funding and no funding will be made available for companies with > 500M EUR annual turnover
- **Industry contributions are committed prior to call launch**: no need for public participants to secure further in-kind contributions

innovative health initiative

Call 13 – Two-stage call

- **Topic 1:** A network to boost the next wave of European innovations in healthcare
- **Topic 2:** An AI foundation toxicology model and framework to support waiving a second species in drug safety studies
- **Topic 3**: Decode the immuno-science of age-related immune-mediated diseases

Launched 2 July, deadline 8 October

→ Call page: https://www.ihi.europa.eu/ihi-call-13

IMPORTANT:

- All applications are evaluated by an independent evaluation panel, industry is not involved
- **The evaluators have one reference: the topic text.**

Eligibility rules on two-stage calls

The following entities are not eligible for funding in two-stage calls:

- For profit entities with more than €500 million annual turnover
- Any entities part of the pre-identified industry consortium (including Contributing Partners)

Please note EFPIA policy is to not request EU funding in any IHI calls (single or two-stage).

Only exception: EFPIA SMEs or mid-caps (>500 mln turnover) who are allowed to request funding, however very few cases so far.

Up-to-date information always on the IHI website



Don't wait until the official call launch: start networking with partners on potential projects as soon as draft texts are available

Open calls: Check out our calls that are open for full proposals (single-stage) or short proposals (two-stage).
Future opportunities : Learn about the topics that are in the pipeline for future calls for proposals.

Draft call texts published early on (at least 3 months before official call launch): https://www.ihi.europa.eu/apply-funding/future-opportunities

Ongoing projects/calls: avoid duplications or overlaps

→ Please refer to IHI website, projects factsheets on Calls 1- (links for each call):

- Call 1: CLAIMS, GUIDE.MRD, IDERHA, IMAGIO, PROMINENT
- Call 2: HEU-EFS, iCARE4CVD
- Call 3: AD-RIDDLE, COMBINE-CT, EDENT1FI, GRIPonMASH, IMPROVE, LIVERAIM, PaLaDin, PREDICTOM, SASICU
- Call 4: ENKORE, NHPig, PharmEco, Project-COMFORT, READI, RealiseD
- Call 5: Accelerate.EU, ILLUMINATE, SEARCHH, SYNTHIA, Thera4Care, UMBRELLA, VICT3R
- Call 6: CAREPATH, GREG
- Call 7: AUTOPIX, BRECISE, EASYGEN, EuroHeartPath, GRACE, INTERCEPT, SHERPA, VIROMARKERS
- Call 8: BRIDGE, UNIFIED, + 2 projects coming soon on osteoarthritis and on prevention of CVDs
- Call 9: ACCESS-AD, AF-B-STEP, COMPASS, END2AMR, EXIT-CVD, GENz-Trials, GUIDE-AI, HospitalAtHome, IMPACT-MED, LIGAND-AI, PATH, PreciseOnco, SEISMIC
- Call 10: topics PFAS, FORTIFY (EHDS & IP), MedTechLabel

+ Launched calls (but projects not started yet):

- Call 11: topics on brain dysfunction, the link between infections and non-communicable diseases, pharmacovigilance, type 1 diabetes, and ambulatory surgical centres (deadline was October 2025)
- **Call 12**, single-stage, submission deadline April 2026, evaluation ongoing.

+ Many IMI2 projects still ongoing, see here.

innovative health initiative

What’s coming next (2027 and after)

- **2027 IHI calls:** IHI Governing Board decision on future calls expected end 2026

- **As from 2028:** As part of the preparations and impact assessment for the next legislative framework governing EU partnerships implemented as JUs, the EC is inviting stakeholders to contribute through a call for evidence.

Outline

1. Introducing the Trade Associations: who we are, what we do and what is our role in IHI?
2. Why participate in IHI calls?
3. How to participate in IHI calls ?
4. How to engage with industry?

Important for you to know: how does industry contribute?

Industry contribution has to be balanced with IHI funding

- Legal requirement for all applications: **at least 45% of private contribution**.
  To be on the safe side & plan for any mitigations -> **go for 50%**

What does industry contributions consist of?

- **IKOP (in-kind in projects)**: personnel, consumables, subcontracting, clinical studies, organisation of meetings, equipment…
- **IKAA** = additional activities contributing to project objectives / IHI objectives (costs usually similar to above)

Companies' commitments usually require green light at management level:

- **Single-stage calls:** reaching out to companies one month before deadline is too late
- **Two-stage calls:** we cannot launch call topics without upfront commitments

Tips for finding partners

- **Start early!** Consortia start forming as soon as draft topics are released
- Good starting point: **build on your existing network**
- Think of **industry as *partners* in a *collaborative* project**, not as suppliers or future customers
- **Reaching out to companies:**
  - **Single-stage calls:** reach out to companies early with clarity on our expertise, the reason you are reaching out, your interest in the topic, why does your idea need a public-private partnership?
  - **Two-stage calls**: do not contact the Industry consortium
- Use the **consortium agreement template** developed by industry specifically for IHI

Contacts at Industry Associations

Enrique Esquivel esquivel@cocir.org

Nicolas Creff nicolas.creff@efpia.eu

Claire Skentelbery C.Skentelbery@europabio.org

Jeroen Schuermans j.schuermans@medtecheurope.org

Charlotte Vernhes charlotte.vernhes@vaccineseurope.eu

Thank you for your attention

efpia

MedTech Europe
from diagnosis to cure

COCIR
Advancing Healthcare

Vaccines Europe
An industry for healthy lives

EuropaBio
The European Association for Bioindustries

BACKUPS:
About industry associations

efpia

MedTech Europe
from diagnosis to cure

COCIR
Advancing Healthcare

Vaccines Europe
An industry for healthy lives

EuropaBio
The European Association for Bioindustries

About EFPIA

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the **biopharmaceutical industry** operating in Europe

Through its direct membership of **37 national associations**, **40 leading pharmaceutical companies**, and a growing number of **small and medium-sized enterprises** (SMEs), EFPIA's mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy

About EFPIA

58
staff members

40
member companies

37
member associations

38
partners in research

14
Vaccines Europe
An industry for healthy lives
members

15
SMEs

More details:

EFPIA The pharmaceutical industry in Europe – selected figures

R&D expenditure: EUR 55 billion

Employment in Europe: 950’000

R&D employment in Europe: 130’000

Trade balance: EUR 220 billion

IMI & IMI2: commitment of EUR 2.4 billion € to almost 200 projects

Source: ***The Pharmaceutical Industry in Figures 2025***: *https://www.efpia.eu/publications/downloads/efpia/the-pharmaceutical-industry-in-figures*

See also:
- EFPIA Data Centre incl. details on R&D investment EU & worldwide
- EFPIA Pipeline Innovation Review 2024

EFPIA - From IMI to IHI

The value of Public Private Partnerships
Europe's Partnership for Health

The Innovative Medicines Initiative: The largest public-private partnership for health research worldwide

€5,276 billion

IMI1 €2 billion from 2008-2014
IMI1 €3,276 billion from 20014-2024

Part of the EU FP7 and
Horizon 2020 R&D funding

- Tools methodologies
- Infrastructures
- Standards
- Accelerators

The Innovative Health Initiative

Budget over 7 years

€1.2 billion funding from EC
€1.2 billion in kind from industry and contributing partners

Institutional partnership with the EU (Joint Undertaking)

Cross sectoral between

- Pharmaceutical sector (EFPIA, Vaccines Europe, EuropaBio)
- Medical technologies sector (MedTech Europe, COCIR)

EFPIA member companies

Full members

Affiliate members

EFPIA member associations

Full members

1. abpi
2. Irish Pharmaceutical Healthcare Association
3. apifarma
4. farmaindustria
5. leem les entreprises du médicament
6. pharma.be
7. Vereniging Innovatieve Geneesmiddelen
8. vfa Die forschenden Pharma-Unternehmen Research-Based Pharmaceutical Companies
9. interpharma
10. FCIO CHEMISCHE INDUSTRIE
11. FARMINDUSTRIA
12. INFARMA
13. LMI
14. lif The research-based pharmaceutical industry
15. LääketeollisuusPharma Industry Finland
16. Lægemiddelindustri foreningen
17. ΣfEE
18. AiFD Araştırmacı İlaç Firmaları Derneği

Affiliate members

1. Association of Pharmaceutical Manufacturers in Estonia
2. Siffa
3. ifpa THE INNOVATIVE PHARMACEUTICAL INDUSTRY ASSOCIATION
4. APRaD Association of Pharmaceutical Research and Development
5. AIFP
6. aifp Asociace inovativního farmaceutického průmyslu
7. iml Dedicated to Life
8. AIPM NEW MEDICINE, NEW HOPE
9. FORUM OF INTERNATIONAL RESEARCH & DEVELOPMENT PHARMACEUTICAL COMPANIES, EIG
10. INOVATIVNA FARMACEUTSKA INICIJATIVA
11. UIPL
12.
13. ARPIM
14. ФАРМАБРЕНД НОВА
15. ARPharM
16. КЕΦΕΑ
17. prima
18. FRUMTÖK



EFPIA member companies

EFPIA SME members

AC Immune

AiCuris
Anti-infective Cures

AM PHARMA

byondis

ENYO PHARMA

idorsia

GENFIT
TOWARDS BETTER MEDICINE

KUSTE BIOPHARMA

minoryx therapeutics

SPEXIS

transgene

SPERO THERAPEUTICS

ProQR

EFPIA member companies

Partners in research

Vaccines Europe

An industry for healthy lives

Vaccines Europe is the specialised vaccines group within EFPIA

- **Innovative research-based companies**

Our members represent innovative research-based global vaccine companies operating in Europe, accounting for a large share of human vaccines used worldwide, as well as European-based small and medium-sized enterprises

- **Our mission**

Foster innovation & value recognition of lifecourse immunisation in Europe to protect people against evolving health challenges

More details: www.vaccineseurope.eu

Abbott
AstraZeneca
Bilthoven Biologicals
Cyrus Poonawalla Group
CSL Seqirus
HIPRA
GSK
MSD
INVENTING FOR LIFE
moderna
Pfizer
novavax
Creating tomorrow's vaccines today.
Takeda
sanofi
VAXCYTE
protect humankind
valneva

Vaccines Europe members

Vaccines Europe (VE) is the specialised vaccine industry group within EFPIA. It represents major innovative research-based global vaccine companies as well as small and medium sized enterprises operating in Europe.

Abbott – A Promise for Life
AstraZeneca
CSL Seqirus
HIPRA
Bilthoven Biologicals – Cyrus Poonawalla Group
GSK
Pfizer
sanofi
moderna
MSD
novavax – Creating tomorrow's vaccines today.
Takeda
valneva
VAXCYTE – protect humankind

The voice of biotechnology in Europe

Ensuring an innovation pipeline for a competitive Europe

The right strategic, legislative and regulatory frameworks for biotechnology to thrive

National, European and global representation

EuropaBio works with company members and national associations across sectors to champion biotechnology

- Bringing **Innovation** to all citizens – making a difference to you
- Enabling **Investment** to deliver next generation technologies to market – creating value & jobs
- Delivering **Excellence** across science and society – translating Europe's research into European benefits

Healthy people and planet

EuropaBio Members

CORPORATE MEMBERS

National associations

NATIONAL ASSOCIATIONS AND BIO REGIONS

ASSOCIATE MEMBERS

The medical technology industry associations

MedTech Europe
from diagnosis to cure

- Medical Devices
- In-Vitro Diagnostics
- Digital health solutions

COCIR
Advancing Healthcare

- Radiotherapy
- Medical imaging
- Health ICT
- Electromedical

innovative health initiative

About MedTech Europe

The European trade association for the medical technology industry including **diagnostics**, **medical devices** and **digital health**.

OUR MEMBERS

150+ multinational corporations*

*medical devices, diagnostics and digital health

50+ medical technology associations

Melanor
BRANSJEORGANISASJONEN FOR MEDTEK OG LAB

Sailab
MedTech Finland

SWEDISH LABTECH

SWEDISH Medtech

The MedTech Industry in Europe

innovative health initiative

€ 170
billion market

930,000+
employees

38,000+
Medical technology companies of which **90%** are SMEs

2,000,000+
medical technologies (Medical Devices, In-Vitro Diagnostics, Digital Health)

#4 highest
In filing patent applications among all industrial sectors

Source: MedTech Europe Facts & Figures 2025

MedTech Europe
from diagnosis to cure

PURPOSE

MedTech Europe's purpose is to make innovative medical technology available to more people, while helping healthcare systems move towards a more sustainable path.

MISSION

Be the **European voice** of the medical technology industries – in Europe and beyond

Highlight the **value** and **contribution** of medical technologies, services and solutions for **patients**, **healthcare systems** and **society**

Facilitate access to **needed medical technologies**

Be a **trusted partner** to EU policymakers and key stakeholders

Contribute actively to EU health-related **policies and legislations**

Foster the **highest ethical standards** in all interactions between the industry and HCPs and HCOs

Based in Brussels, Belgium with 50 staff members

MedTech Europe priorities

- Legal and Compliance
- Market Access and Economic Policy
- Medical Technology Regulations
- Digital Health
- International Affairs
- Environmental and social sustainability
- Market data
- **Research and Innovation**

- + sector groups: e.g. cancer, diabetes, cardiovascular, AMR, Robotic Assisted Surgery, ….

More info: www.medtecheurope.org

MedTech Europe priorities via IHI

Europe's attractiveness and competitiveness as an industrial location for innovation via 3 axes:

- Sustainability
- Digital, AI and RWD
- Healthcare delivery improvement

Introduction to COCIR



- COCIR is a non-profit trade association, founded in 1959 and having offices in Brussels and China, representing the medical technology industry in Europe
- COCIR covers 4 key industry sectors
  - Medical Imaging
  - Radiotherapy
  - Health ICT
  - Electromedical
- Our Industry leads in state-of-art advanced technology and provides integrated solutions covering the complete care cycle

COCIR
Advancing Healthcare

Company Members

National Trade Associations Members

Healthtech Finland
FINLAND

LE DISPOSITIF MÉDICAL SNITEM Pour faire avancer la santé
FRANCE

bvitg
GERMANY

zvei electrifying ideas
GERMANY

ETOSZ ASSOCIATION OF HEALTH TECHNOLOGY SUPPLIERS AND MEDICAL DEVICE MANUFACTURERS
HUNGARY

CONFINDUSTRIA Dispositivi Medici
ITALY

Associação Portuguesa das Empresas de Dispositivos Médicos apormed tecnologias para a saúde
PORTUGAL

FMed
THE NETHERLANDS

FME POWERED BY DUTCH TECHNOLOGY
THE NETHERLANDS

Fenin Tecnología Sanitaria
SPAIN

SWEDISH Medtech
SWEDEN

TIP GÖR DER
TURKEY

What makes IHI different from regular Horizon Europe calls?

- IHI equally **associates the EC and Industry in priority setting**
- Each IHI project requires ideally **50% of the budget from industry**
  ...unlike Horizon where there is no minimum funding from industry
- IHI aims at delivering (direct and concrete) **impact on the healthcare delivery**
- The **average budget of an IHI project is usually >15 M€**, sometimes much more (ex: 60 M€)… unlike Horizon projects with budget on average <15 M€